Entrada Therapeutics (TRDA) Director Kush Parmar Sells Shares

What Happened

• Kush M. Parmar, M.D., Ph.D., a director of Entrada Therapeutics (TRDA), reported open-market sales totaling 155,255 shares across three transactions between Aug 6 and Aug 10, 2026, generating roughly $1,078,937 in proceeds.
  • Aug 6, 2026 — 10,494 shares reported at a weighted average price of $7.00 (proceeds ≈ $73,458).
  • Aug 7, 2026 — 52,317 shares reported at a weighted average price of $6.85 (proceeds ≈ $358,371).
  • Aug 10, 2026 — 92,444 shares reported at a weighted average price of $7.00 (proceeds ≈ $647,108).
• These were sales (S) — not purchases or option exercises — which are generally considered routine liquidity events rather than an explicit bullish signal.

Key Details

• Transaction dates and reported weighted-average price ranges (per footnotes):
  • Aug 6 sale: weighted avg $7.00; actual prices ranged $6.90–$7.11 (F1).
  • Aug 7 sale: weighted avg $6.85; actual prices ranged $6.80–$7.01 (F3).
  • Aug 10 sale: weighted avg $7.00; actual prices ranged $6.84–$7.20 (F4).
• Total shares sold: 155,255; approximate total proceeds: $1,078,937.
• Shares ownership after the transactions: not specified in the provided excerpt of the Form 4.
• Beneficial ownership notes: some shares involved are held by investment vehicles (5AM Ventures V, L.P. and 5AM Opportunities I, L.P.). Dr. Parmar is a managing member of the affiliated general partner entities and may be deemed to share voting and investment power over those holdings but disclaims beneficial ownership except to the extent of his pecuniary interest (F2, F5).
• Filing date: Form 4 filed Aug 10, 2026, reporting sales from Aug 6–10, 2026. No late-filing flag is indicated in the provided information.

Context

• These were straight sales reported as open-market or private sales (code S). Sales by insiders can reflect personal liquidity needs or portfolio management and, by themselves, do not necessarily indicate a change in view about the company.
• The filing includes weighted-average prices and footnote ranges; the reporting person offered to provide breakdowns of the prices upon request — useful if you want exact per-trade pricing.